

Notice Regarding the Signing of the Agreements on the Establishment of the Joint Ventures with Ping An Insurance, the Establishment of a New Subsidiary, the Signing of the Agreements on Transfer of Subsidiary Shares and Equity Stakes, and the Disposal of Treasury Shares by Way of Third-Party Allotment

OSAKA, Japan, July 13, 2020 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D., hereafter “Shionogi” or “the Company”) today announced that, at a meeting held on July 13, 2020, its Board of Directors, pursuant to the Basic Agreement on the Capital Alliance (hereinafter, “the Basic Agreement”) dated March 30, 2020 between Shionogi and Ping An Insurance (Group) Company of China Ltd. (Headquarters: Guangdong Province, China; hereinafter, “Ping An Insurance”), passed resolutions to sign an agreement with Ping An Life Insurance of China, Ltd. (Headquarters: Guangdong Province, China; hereinafter, “Ping An Life”), which possesses equity-investment functions and is a subsidiary of Ping An Insurance, concerning the establishment of a joint venture called Ping An Shionogi Company Ltd. (Headquarters: Shanghai; hereinafter, “the Joint Venture (Shanghai)”), and an agreement with Shionogi (Hong Kong) (as defined hereinafter) and Tutum Japan Healthcare Limited (Headquarters: Cayman Islands; hereinafter, “Ping An Overseas”), which is a subsidiary of China Ping An Insurance Overseas (Holdings) Limited and an indirect subsidiary of Ping An Group, concerning the establishment of a joint venture (Headquarters: Hong Kong; hereinafter, “the Joint Venture (Hong Kong)”). Hereinafter, the Joint Venture (Shanghai) and the Joint Venture (Hong Kong) are collectively referred to as “the Joint Ventures” and the two agreements concerning their establishment are collectively referred to as “the Agreements.” Upon the execution of the Agreements, the pre-execution conditions for Shionogi’s disposal of treasury shares by way of third-party allotment to Ping An Life (hereinafter, “the Third-Party Allotment”), which we announced in “Notice Regarding the Signing of the Basic Agreement on the Capital and Business Alliance with Ping An Insurance and the Disposal of Treasury Shares by Way of Third-Party Allotment”¹ dated March 30, 2020, will be satisfied.

Furthermore, with the aim of overseeing the Joint Ventures locally, we passed a resolution to establish Shionogi (Hong Kong) Company Ltd. (Headquarters: Hong Kong; hereinafter, “Shionogi (Hong Kong)”) as a wholly-owned subsidiary of Shionogi.

In addition, we passed a resolution concerning the signing of two equity-stake transfer agreements (hereinafter, “the Equity-Stake Transfer”) to transfer all equity stakes in each of Shenzhen Liancheng Medical Company Limited (Headquarters: Guangdong Province, China; hereinafter, “the Shenzhen Sales Company”), which possesses sales functions, and Nanjing Chang'ao Medicine Technology Co., Ltd. (Headquarters: Jiangsu Province, China; hereinafter, “the Nanjing Factory”), which possesses pharmaceuticals manufacturing functions (both the Shenzhen Sales Company and the Nanjing Factory are under the control of C&O Pharmaceutical Technology (Holdings) Limited (Headquarters: Bermuda; hereinafter, “C&O”), which is a wholly-owned subsidiary of Shionogi), to the Joint Venture

(Shanghai) and a share transfer agreement (hereinafter, “the Share Transfer”) to transfer all shares in Shionogi Healthcare Co., Ltd. (Headquarters: Chuo-ku, Osaka; hereinafter, “Shionogi Healthcare”), which is in the over-the-counter pharmaceuticals business, to the Joint Venture (Hong Kong).

I. Outline of the Establishment of the Joint Ventures

1. Purposes of the Establishment of the Joint Ventures, the Equity-Stake Transfer, and the Share Transfer

As we announced in “Notice Regarding the Signing of the Basic Agreement on the Capital and Business Alliance with Ping An Insurance and the Disposal of Treasury Shares by Way of Third-Party Allotment”¹ dated March 30, 2020, Shionogi, Ping An Group and Ping An Life have signed the Basic Agreement for the purpose of pursuing, through the Joint Ventures, the following as main businesses:

- (i) Build a data-driven^{Note 1} drug discovery/development platform, and use the platform to discover and develop pharmaceutical products (new, generic and over-the-counter drugs)
- (ii) Build a manufacturing and quality control system using AI technology, and use the system to assure the quality of pharmaceutical products (new, generic and over-the-counter drugs)
- (iii) Build a sales and distribution platform utilizing O2O (Online to Offline)^{Note 2}, and use the platform to sell and distribute pharmaceutical products (new, generic and over-the-counter drugs)

(1) The Joint Venture (Shanghai) (Ping An Shionogi Company Ltd.)

Pursuant to the Agreements, we have agreed to establish the Joint Venture (Shanghai), with to-be newly-established Shionogi (Hong Kong) holding a 51% equity stake and Ping An Life holding a 49% equity stake, for the purpose of executing (i)-(iii) above. Furthermore, all equity stakes in each of the Shenzhen Sales Company and the Nanjing Factory, which are subsidiaries of C&O, will be transferred to the Joint Venture (Shanghai). The plan is for the Joint Venture (Shanghai) to be positioned as the base of Shionogi’s China and Asia operations, and to pursue businesses (i)-(iii) above. Specific details of businesses already agreed at the time of writing are as follows:

(i) Build a data-driven drug discovery/development platform, and use the platform to discover and develop pharmaceutical products (new, generic and over-the-counter drugs) thereof:

With a focus on infectious disease, CNS disorders, and pain, over many years Shionogi has amassed a wealth of knowledge about disease and strong drug-discovery capabilities, and by combining these competencies with Ping An’s lifestyle-related big data and AI analytical technology possessed by Ping An, we will be establishing a drug discovery/development platform that will allow us to efficiently create high-value-added, innovative medicines and healthcare services and deliver individually-optimized solutions that meet the respective needs of customers. We will also be granting exclusive negotiating rights in the Asia territory (including China) with respect to both approved and under-development products for which Shionogi owns the rights to the Joint Venture, and nurturing it as a development center for drugs that Shionogi is developing globally. As soon as the Joint Venture is established, we plan to sign licensing agreement for the territory concerning cefiderocol, a drug for treating multi-drug-resistant Gram-negative bacterial infections, and naldemedine, a drug for treating opioid-induced constipation. We are also considering licensing

potential drugs for novel coronavirus disease (vaccines, therapeutic drugs, and diagnostic drugs) that are currently under development in Japan to the Joint Venture (Shanghai) when the timing is appropriate.

(ii) Build a manufacturing and quality control system using AI technology, and use the system to assure the quality of pharmaceutical products (new, generic and over-the-counter drugs):

To enhance pharmaceutical manufacturing and quality control, we will be fusing the manufacturing and quality control technology and knowhow Shionogi has acquired over the years with the AI technology^{Note 3} possessed by Ping An to develop a new manufacturing and quality control system. We will be using AI to monitor the frontline of manufacturing and analysis in real time and make processes transparent, and by making the previous system more efficient, we will be aiming to put together and deploy an innovative pharmaceutical manufacturing and quality control system that offers both high quality and low costs. Initially, we plan to start with trial operation at the Nanjing Factory, which is going to be brought under the wing of the Joint Venture (Shanghai).

(iii) Build a sales and distribution platform utilizing O2O (Online to Offline), and use the platform to sell and distribute pharmaceutical products (new, generic and over-the-counter drugs):

We will be aiming for growth by collaborating with Ping An Good Doctor. Affiliated to Ping An Group, Ping An Good Doctor has established a comprehensive, one-stop healthcare ecosystem. It is today the largest mobile medical application in China in terms of user scale, with 315.2 million registered users by the end of 2019. It leverages on its in-house full-time medical team and its proprietary AI-based medical system to cover 24/7 end-to-end services including online consultation, prescription, referral, appointment, second medical opinion and drug delivery. Shionogi will begin supplying generic drugs it sells in China through the Shenzhen Sales Company and the Nanjing Factory, as well as over-the-counter drugs sold by Shionogi Healthcare via this healthcare platform. At the same time, Shionogi will be moving quickly to launch new drugs, such as cefiderocol, for which it has obtained approval globally in the Asia territory (including China). Furthermore, by not only offering our own approved and under-development drugs, but also actively launching new drugs, generics, and over-the-counter drugs for which there are high levels of medical need, we will be working to further expand our product lineup and raise customer satisfaction.

Note 1: Refers to the judgement/action based on data such as real-world data, marketing data, web analysis data, etc.

Note 2: Refers to the promotion of marketing and sales activities by combining online websites and offline physical stores.

Note 3: Refers to the technologies that use software etc. to artificially reproduce certain human intellectual behaviors or to monitor and analyze pictures and sounds and detect or forecast abnormal or illegal situations.

(2) The Joint Venture (Hong Kong) (Ping An Shionogi (Hong Kong) Company Ltd.)

Pursuant to the Agreements, we have agreed to establish the Joint Venture (Hong Kong), with to-be-newly-established Shionogi (Hong Kong) holding a 51% shareholding and Ping An Overseas holding a 49% shareholding, for the purpose of executing (i)-(iii) above by performing intellectual-property license management and exporting/importing products from/to countries in the Asia territory

(including China). Furthermore, all shares in Shionogi Healthcare will be transferred to Joint Venture (Hong Kong), and Shionogi Healthcare products will be supplied to customers in the Asia territory (including China). Moreover, we expect the new platform business that will be created as a result of the establishment of the Joint Ventures and the Share Transfer and will cover the entire spectrum from prevention to treatment, as well over-the-counter drugs developed by the Joint Ventures, to be made available in Japan. Through this, we will be aiming for the Japan business, the most important business for Shionogi Healthcare, to make further strives forward.

On June 1, 2020, Shionogi announced the Shionogi Transformation Strategy 2030 (hereinafter, “STS2030”), our new medium-term business plan, which comprises our vision for 2030 and the growth strategy we will be following to achieve that vision². The vision is “Building Innovation Platforms to Shape the Future of Healthcare,” and the concept behind the establishment of the Joint Ventures with Ping An matches that. The first five years of STS2030 is positioned as STS Phase 1, and our basic course of action for this phase will be to “realize transformation to a new growth as a total healthcare company” by pursuing R&D and top-line (sales) strategies to create new value and a transformed management foundation strategy to realize value creation. Under our top-line strategy, we are positioning China as a target area alongside Japan and the U.S., and the two Joint Ventures to be established will be playing a central role in bringing about Shionogi’s business transformation into total healthcare company, establishing a new drug-discovery/development model, and delivering top-line growth.

2. Outline of the Joint Ventures to Be Established (Plan)

(1) Outline of the Joint Venture (Shanghai)

(1) Name of Company	Ping An-Shionogi Co., Ltd. (company name is subject to approval)
(2) Location	Kaibin Centre, No. 199 Kaibin Road, Xuhui District, Shanghai, China
(3) Representative	Tatsumori Yoshida, Chairman and CEO
(4) Date of Foundation	Planned for August 2020
(5) Business Description	Investment, pharmaceuticals, clinical-laboratory drugs/instruments research, development, sale, etc., IT-related technology development, services
(6) Fiscal-year End	December
(7) Capital	JPY 45 billion equivalent in RMB
(8) Shareholders	Shionogi (Hong Kong) 51%, Ping An Life 49%

(2) Outline of the Joint Venture (Hong Kong)


(1) Name of Company	Ping An-Shionogi (Hong Kong) Limited (company name is subject to approval)
(2) Location	Unit 911-12 Silvercord Tower 2, 30 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong

Press Release



(3) Representative	Tatsumori Yoshida, Chairman and CEO
(4) Date of Foundation	Planned for August 2020
(5) Business Description	Equity investment, financial services, IP license management, import/export of products from/to Asian countries
(6) Fiscal-year End	March
(7) Capital	JPY 5 billion
(8) Shareholders	Shionogi (Hong Kong) 51%, Ping An Overseas 49%

(2) Capital Relationship Between the Joint Ventures



3. Outline of the Other Parties to the Joint Ventures

(1) Other Party to the Joint Venture (Shanghai) (as of December 31, 2019)

(1) Name of Company	Ping An Life Insurance Company of China, Ltd.
(2) Location	14th, 15th, 16th, 37th, 41st, 44th, 45th and 46th Floors, Ping An Finance Center, No.5033 Yi Tian Road, Futian District, Shenzhen, Guangdong Province, China
(3) Representative	Ding Xinmin, Chairman
(4) Business Description	Life insurance

Press Release



(5) Capital	JPY 527,416 million yen	
(6) Date of Foundation	December 17, 2002	
(7) Number of Shares Issued	33,800,000,000 shares	
(8) Fiscal-year End	December	
(9) Number of Employees	96,008 (Consolidated)	
(10) Main Customers	Private individuals	
(11) Main Banks	Bank of China, Industrial and Commercial Bank of China, China Construction Bank, Ping An Bank	
(12) Major Shareholders and Shareholding Ratios	Ping An Insurance (Group) Company of China, Ltd.	99.51%
(13) Relationship Between the Parties		
Capital Relationship	Number of shares of the allottee owned by Shionogi	Nil
	Number of shares of Shionogi owned by the allottee	Nil
Personal Relationship	There is no relationship to be disclosed between the parties.	
Transactional Relationship	There is no relationship to be disclosed between the parties.	
Status as Related Party	There is no relationship to be disclosed between the parties.	

Exchange rates are based on the interim rate of JPY 100 = RMB 6.4086 as of December 31, 2019, as announced by the Bank of China.

(2) Other Party to the Joint Venture (Hong Kong) (as of December 31, 2019)

(1) Name of Company	Tutum Japan Healthcare Limited
(2) Location	4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands
(3) Representative	KUI Kaipin, Director
(4) Business Description	Investment Holding
(5) Capital	JPY 4,020,932,818
(6) Date of Foundation	March 29, 2019
(7) Number of Shares Issued	3
(8) Fiscal-year End	December
(9) Number of Employees	N/A
(10) Main Customers	N/A
(11) Main Banks	Bank of China
(12) Major Shareholders and Shareholding Ratios	100% held by China Ping An Insurance Overseas (Holdings) Limited

(13) Relationship Between the Parties		
Capital Relationship	Number of shares of the allottee owned by Shionogi	Nil
	Number of shares of Shionogi owned by the allottee	Nil
Personal Relationship	There is no relationship to be disclosed between the parties.	
Transactional Relationship	There is no relationship to be disclosed between the parties.	
Status as Related Party	There is no relationship to be disclosed between the parties.	

Exchange rates are based on the interim rate of USD 1 = JPY 108.53 as of December 31, 2019, as announced by the U.S. Department of the Treasury.

(3) Outline of Parent Company of Other Parties to the Joint Ventures (as of December 31, 2019)

(1) Name of Company	Ping An Insurance (Group) Company of China, Ltd.	
(2) Location	Ping An Finance Center, No. 5033 Yi Tian Road, Futian District, Shenzhen, Guangdong Province, China	
(3) Representative	Ma Mingzhe, Chairman [& CEO]	
(4) Business Description	Insurance Business, Banking Business, Asset Management Business, Technology Business	
(5) Capital	JPY 285,242 million	
(6) Date of Foundation	March 21, 1988	
(7) Number of Shares Issued	10,832,664,498 A-Shares, 7,447,576,912 H-Shares	
(8) Fiscal-year End	December	
(9) Number of Employees	1.8 million (including 1.42 million insurance sales representatives) (Consolidated)	
(10) Main Customers	—	
(11) Main Banks	—	
(12) Major Shareholders and Shareholding Ratios	Hong Kong Securities Clearing Company Nominees Limited	33.44%
	Shenzhen Investment Holdings Co., Ltd.	5.27%
	Hong Kong Securities Clearing Company Limited	4.48%
	New Orient Ventures Limited	3.91%
	Business Fortune Holdings Limited	3.27%
	China Securities Finance Corporation Limited	2.99%
	Central Huijin Asset Management Ltd.	2.65%
	Shum Yip Group Limited	1.41%
	Dacheng Fund-Agricultural Bank of China -Dacheng	
	Zhongzheng Financial Asset Management Plan	1.10%
	Huaxia Fund-Agricultural Bank of China -Huaxia Zhongzheng	
	Financial Asset Management Plan	1.09%

(13) Relationship Between the Parties		
Capital Relationship	Number of shares of the allottee owned by Shionogi	Nil
	Number of shares of Shionogi owned by the allottee	Nil
Personal Relationship	There is no relationship to be disclosed between the parties.	
Transactional Relationship	There is no relationship to be disclosed between the parties.	
Status as Related Party	There is no relationship to be disclosed between the parties.	

Exchange rates are based on the interim rate of JPY 100 = RMB 6.4086 as of December 31, 2019, as announced by the Bank of China.

II. Outline of the New Subsidiary

1. Purpose of Establishment of the New Subsidiary

With a view to building a long-term partnership with Ping An Group, we plan to establish a local subsidiary in Hong Kong to serve as a base for overseeing the Joint Ventures locally and assisting them with business administration.

2. Outline of the Subsidiary to be Newly Established

(1) Name of Company	Shionogi (Hong Kong) Limited.
(2) Location	Unit 911-12 Silvercord Tower 2, 30 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong
(3) Representative	Masaki Tomiyama, Chairman
(4) Date of Foundation	Planned for July 2020
(5) Description of Business	Assistance with business administration in China/Asia
(6) Fiscal-year End	March
(7) Capital	JPY 25.7 billion
(8) Shareholders	Shionogi 100%

III. Outline of the Equity-Stake Transfer

1. Purpose of the Equity-Stake Transfer

Please refer to “1. Purposes of the Establishment of the Joint Ventures, the Equity-Stake Transfer, and the Share Transfer.” Note that even after the Equity-Stake Transfer, the plan is for the Shenzhen Sales Company and the Nanjing Factory to remain consolidated subsidiaries of Shionogi, so there will be no changes in consolidation.

2. Outline of the Equity Stakes to be Transferred

(1) Outline of Subsidiary (the Shenzhen Sales Company) subject to the Equity-Stake Transfer to the Joint Venture (Shanghai)

(1) Name of Company	Shenzhen Liancheng Medical Company Limited
---------------------	--

(2) Location	Room 501-516, Jihao Building, Shennan East Road, Luohu District, Shenzhen, Guangdong Province, China
(3) Representative	Xu Yan, Chairman
(4) Date of Foundation	March 29, 2004
(5) Description of Business	Wholesale and export/import (and related operations) of Chinese medicines, chemically-derived medicines, pharmaceutical preparations, antibiotic preparations, and biochemical medicines
(6) Fiscal-year End	December
(7) Capital	JPY 3.88120 billion
(8) Shareholders	Angel Zone Development Group Limited 100%

The exchange rate applied was the average of the bid and ask rates quoted by the Bank of China on March 31, 2020, which was JPY 15.65 to the Chinese yuan.

(2) Outline of Subsidiary (the Nanjing Factory) subject to the Equity-Stake Transfer to the Joint Venture (Shanghai)

(1) Name of Company	Nanjing Chang'ao Medicine Technology Co., Ltd.
(2) Location	63 Kexin Road, Jiangbei New District, Nanjing, Jiangsu Province, China
(3) Representative	Yasuhiro Miyako, Chairman
(4) Date of Foundation	August 13, 1997
(5) Description of Business	Development and production of pharmaceuticals (production and management in accordance with the production permits awarded by provincial bureaus of the National Medical Products Administration), sale of own products, regular cargo transportation by road
(6) Fiscal-year End	December
(7) Capital	JPY 5.09557 billion
(8) Shareholders	OME (H.K.) Laboratories Limited 100%

The exchange rate applied was the average of the bid and ask rates quoted by Sumitomo Mitsui Banking Corporation the Bank of China on March 31, 2020, which was USD 1 = JPY 108.81.

3. Outline of Other Party to the Equity Transfer

Please refer to “2. Outline of the Joint Ventures to Be Established (Plan) (1) Outline of the Joint Venture (Shanghai).”

IV. Outline of the Share Transfer

1. Purpose of the Share Transfer

Please refer to “1. Purposes of the Establishment of the Joint Ventures, the Equity-Stake Transfer, and the Share Transfer.” Note that even after the Share Transfer, the plan is for the Shionogi Healthcare to remain a consolidated subsidiary of Shionogi, so there will be no changes in consolidation.

2. Outline of the Shares to Be Transferred

(1) Outline of Subsidiary subject to the Share Transfer to the Joint Venture (Hong Kong)

(1) Name of Company	Shionogi Healthcare Co., Ltd.
(2) Location	Yodoyabashi Square, 6-18, Kitahama 2-chome, Chuo-ku, Osaka-shi, Osaka
(3) Representative	Satoru Yoshimoto, Representative Director and President
(4) Date of Foundation	January 15, 2016
(5) Description of Business	Development, manufacture, and sale of healthcare products such as over-the-counter pharmaceuticals, quasi-drugs, managed-care devices, health foods, etc.
(6) Fiscal-year End	March
(7) Capital	JPY 10 million
(8) Shareholders	Shionogi 100%

3. Outline of Other Party to the Share Transfer

Please refer to “2. Outline of the Joint Ventures to Be Established (Plan) (2) Outline of the Joint Venture (Hong Kong)

V. Schedule

(1) Resolution of the Board of Directors	July 13, 2020
(2) Execution of the Joint Venture Agreement	Late July 2020 (Plan)
(3) Establishment of the Joint Ventures	
Ping An Shionogi Company Ltd.	August 2020 (Plan)
Ping An Shionogi (Hong Kong) Company Ltd.	August 2020 (Plan)
(4) Establishment of the Subsidiary	July 2020 (Plan)
(5) Execution of the Equity-Stake Transfer Agreement	August 2020 (Plan)
Execution of the Equity-Stake Transfer	September 2020 (Plan)
(6) Execution of the Share Transfer Agreement	August 2020 (Plan)
Execution of the Share Transfer	December 2020 (Plan)

VI. Disposal of Treasury Stock by Way of the Third-Party Allotment

The Third-Party Allotment had prerequisites for execution including the following: 1). The joint venture agreement concerning the establishment of the Joint Ventures has been concluded between Shionogi and Ping An Group or its group company; and 2). The allottee has obtained the various licenses required to undertake the Third-Party Allotment. Upon the signing of the Agreements, all the conditions for execution will have been met, and we plan to promptly execute the Third-Party Allotment on or around the fifth business day from the day the Agreements are signed, with the details as outlined below. For details of the Third-Party Allotment, please refer to “Notice Regarding the

Press Release



Signing of the Basic Agreement on the Capital and Business Alliance with Ping An Insurance and the Disposal of Treasury Shares by Way of Third-Party Allotment^{*1} dated March 30, 2020.

Outline of Disposal

(1) Period of Share Disposal	From July 1, 2020 to July 31, 2020 (Plan)
(2) Number of Shares to Be Disposed of	6,356,000 shares of Shionogi's common stock
(3) Disposal Price	JPY 5,276 per Share
(4) Amount of Capital to be Raised	JPY 33,534,256,000
(5) Method of Offering or Disposal (Allottee)	By way of the Third-Party Allotment (Ping An Life)
(6) Other	Each of the foregoing items is conditional upon the taking effect of the Securities Registration Statement filed in accordance with the Financial Instruments and Exchange Act.

VII. Future Outlook

We are currently carefully examining the impact that the establishment of the Joint Ventures, the establishment of the subsidiary, the Share Transfer, and the Equity-Stake Transfer will have on Shionogi's consolidated operating results for the year to March 2021. If, as a result of these examinations, we deem that our operating forecasts need to be revised, we will make prompt public announcement.

About Shionogi

Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of "supplying the best possible medicine to protect the health and wellbeing of the patients we serve." Shionogi's research and development currently targets two therapeutic areas: infectious diseases, and pain/CNS disorders. For over 60 years, Shionogi has developed and commercialized innovative oral and parenteral anti-infectives. In addition, Shionogi is engaged in new research areas, such as obesity/geriatric metabolic diseases and oncology/immunology. Contributing to the health and QOL of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit www.shionogi.com/global/en/.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations

in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also, for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

For further information, contact:

Shionogi & Co., Ltd.

Corporate Communications

Telephone: +81-6-6209-7885

Fax: +81-6-6229-9596

References:

1. [Press Release: March 30, 2020](#)

Notice Regarding the Signing of the Basic Agreement with Ping An Insurance for a Capital and Business Alliance including the Disposal of Treasury Shares by Way of Third-Party Allotment

2. [Press Release: June 1, 2020](#)

Notice Regarding a New Medium-Term Business Plan